Flupentixol + MelitracenThird Party Manufacturing in India

Flupentixol plus Melitracen is a fixed-dose combination that modulates both dopaminergic and serotonergic-noradrenergic neurotransmitter systems. Flupentixol, a thioxanthene derivative, acts as a dopamine D1 and D2 receptor antagonist. At the low doses used in this combination, flupentixol preferentially blocks presynaptic dopamine autoreceptors, leading to enhanced dopamine release in the prefrontal cortex. This low-dose dopaminergic activation produces anxiolytic and antidepressant effects without the extrapyramidal side effects seen at antipsychotic doses. Melitracen, a tricyclic antidepressant, inhibits the reuptake of serotonin and noradrenaline at the presynaptic neuronal membrane, thereby increasing the synaptic concentration of these monoamine neurotransmitters. It also exhibits moderate anticholinergic activity and antihistaminic properties. The combination of a low-dose antipsychotic with a tricyclic antidepressant creates a synergistic effect for managing mixed anxiety-depressive states. Flupentixol counteracts the sedative effects of melitracen through its activating dopaminergic properties, while melitracen provides the mood-elevating and anxiolytic effects through enhanced monoaminergic transmission. This balanced pharmacological profile makes the combination suitable for psychosomatic and neurotic disorders where both anxiety and low mood are present.

Therapeutic Uses

Flupentixol + Melitracen combination is prescribed for:

• Anxiety with Depression: This combination is particularly effective for patients presenting with mixed anxiety and depressive symptoms, where the anxiolytic effect of low-dose flupentixol complements the antidepressant action of melitracen.

• Psychosomatic Disorders: The combination is widely used for psychosomatic complaints such as tension headaches, irritable bowel syndrome, and chronic pain syndromes with a psychological component.

• Asthenia and Fatigue: In patients with neurasthenia or stress-related fatigue, the combination provides symptomatic relief through its mild psychostimulant and mood-elevating properties.

• Neurotic Disorders: For adjustment disorders, somatoform disorders, and other neurotic conditions where anxiety and depressive features coexist, this combination offers a rational pharmacological approach.

Why Manufacturers Choose Flupentixol + Melitracen

The Flupentixol + Melitracen combination (commonly known by the brand name Deanxit) is one of the most widely prescribed psychiatric fixed-dose combinations in India. Its popularity among general practitioners and psychiatrists creates substantial and consistent demand for third party manufacturing. Indian pharmaceutical companies with WHO-GMP certification regularly manufacture this combination for both domestic PCD franchise distribution and export to markets across Asia and Africa. The tablet formulation (0.5mg + 10mg) is the most common dosage form, though the combination is also available in some markets as a lower strength variant. The high prescription volume, coupled with repeat purchase patterns in chronic psychiatric conditions, makes this one of the most commercially reliable combinations for contract manufacturing partners seeking long-term production arrangements.